IM
IMRX
Immuneering Corp
$4.19
+1.70%
$271.1M
No data for this timeframe.
Vol
Market Cap$271.1M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders43 funds
Inst. Value$102.6M
Inst. Activity3 buys / 5 sells
Reddit Sentiment50° Neutral
SEC Reports4
Press Releases2
Recent Activity
Jun 11, 2026
fda
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + m
Jun 11, 2026
SEC
Five mega-passive institutional investors (Vanguard, BlackRock, State Street, Fidelity, Morgan Stanley) significantly in
INST-CLUSTER — Impact 3/10
Jun 11, 2026
Insider
Feinberg Peter was granted 33,350 shares
Director
Jun 11, 2026
Insider
KEATING LAURIE was granted 33,350 shares
Director
Jun 11, 2026
Insider
CARPENTER ROBERT J was granted 33,350 shares
Director
Jun 1, 2026
SEC
Immuneering announced updated Phase 2a data for atebimetinib (IMM-1-104) in first-line pancreatic cancer, showing 17.3-m
8-K — Impact 7/10
May 15, 2026
SEC
Immuneering reported Q1 2026 EPS of -$0.21, beating consensus of -$0.25 by 16%, with no revenue. The key catalyst is upc
PRESS-RELEASE — Impact 7/10
Inst.
MARSHALL WACE, LLP — DOUBLED
1,996,585 shares ($10.5M)
Price Targets
$17.00
+305.7% upside
Strong Buy
Current $4.19
Low $11.00
Median $14.50
High $30.00
6 analysts
$11.00
$30.00
Analyst Ratings
4Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 19, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Mar 9, 2026 | Needham | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.27 ▲ +3.8% | $-0.31 — $-0.25 | 32% YoY | 6 |
| Next Q | $-0.32 ▲ +4.0% | $-0.37 — $-0.26 | 17% YoY | 6 |
| Current FY | $-1.14 ▲ +4.2% | $-1.30 — $-0.95 | 11% YoY | 6 |
| Next FY | $-1.34 ▲ +1.1% | $-1.71 — $-0.62 | -18% YoY | 6 |
Latest Reports
NEUTRAL
INST-CLUSTER
3/10
Five mega-passive institutional investors (Vanguard, BlackRock, State Street, Fidelity, Morgan Stanley) significantly in
Jun 11, 2026
BULLISH
8-K
7/10
Immuneering announced updated Phase 2a data for atebimetinib (IMM-1-104) in first-line pancreatic cancer, showing 17.3-m
Jun 1, 2026
BULLISH
Press
7/10
Immuneering Corporation announced that updated Phase 2a data from an expanded cohort of 55 first-line pancreatic cancer
Apr 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $51.1M | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $12.1M | — |
| MARSHALL WACE, LLP | $10.5M | DOUBLED |
| BlackRock, Inc. | $7.9M | DOUBLED |
| CITADEL ADVISORS LLC | $2.4M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 11, 2026 | Feinberg Peter | A | $0.00 |
| Jun 11, 2026 | KEATING LAURIE | A | $0.00 |
| Jun 11, 2026 | CARPENTER ROBERT | A | $0.00 |
| Jun 11, 2026 | HAUSMAN DIANA | A | $0.00 |
| Jun 11, 2026 | Schall Thomas | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
43 institutional holders with $102.6M total value (21,337,603 shares) as of 2026-Q1. Top holders: FMR, VANGUARD, MARSHALL. Net selling activity: 5 institutions trimmed/exited vs 3 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 9,697,938 | $51.1M | 49.8% | DOUBLED +3876.0% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2,288,341 | $12.1M | 11.8% | — |
| 3 | MARSHALL WACE, LLP | 1,996,585 | $10.5M | 10.3% | DOUBLED +180.5% |
| 4 | BlackRock, Inc. | 1,507,258 | $7.9M | 7.7% | DOUBLED +113.1% |
| 5 | CITADEL ADVISORS LLC | 447,278 | $2.4M | 2.3% | — |
| 6 | Connor, Clark & Lunn Investment Management Ltd. | 400,363 | $2.1M | 2.1% | DOUBLED +201.8% |
| 7 | GOLDMAN SACHS GROUP INC | 327,655 | $1.7M | 1.7% | — |
| 8 | VANGUARD FIDUCIARY TRUST CO | 322,038 | $1.7M | 1.7% | — |
| 9 | MORGAN STANLEY | 296,067 | $1.6M | 1.5% | TRIM -39.5% |
| 10 | STATE STREET CORP | 268,520 | $1.4M | 1.4% | NEAR_EXIT -88.8% |
| 11 | TWO SIGMA INVESTMENTS, LP | 244,771 | $1.3M | 1.3% | ADD +92.0% |
| 12 | WELLINGTON MANAGEMENT GROUP LLP | 156,424 | $824.4K | 0.8% | — |
| 13 | BANK OF AMERICA CORP /DE/ | 150,847 | $795.0K | 0.8% | TRIM -29.6% |
| 14 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 139,300 | $734.1K | 0.7% | — |
| 15 | HighTower Advisors, LLC | 131,286 | $691.9K | 0.7% | — |
| 16 | BARCLAYS PLC | 121,978 | $642.8K | 0.6% | DOUBLED +122.9% |
| 17 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 105,507 | $556.0K | 0.5% | — |
| 18 | Hudson Bay Capital Management LP | 95,889 | $505.3K | 0.5% | — |
| 19 | TD ASSET MANAGEMENT INC | 94,340 | $497.2K | 0.5% | TRIM -52.9% |
| 20 | Brevan Howard Capital Management LP | 86,236 | $454.5K | 0.4% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MARSHALL WACE, LLP | DOUBLED | 711,875 | 1,996,585 | +180.5% | $10.5M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | DOUBLED | 132,680 | 400,363 | +201.8% | $2.1M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 489,617 | 296,067 | -39.5% | $1.6M | 2026-Q1 |
| STATE STREET CORP | NEAR_EXIT | 2,402,238 | 268,520 | -88.8% | $1.4M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 214,341 | 150,847 | -29.6% | $795.0K | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 152,300 | 72,875 | -52.2% | $384.1K | 2026-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 22,344 | 37,344 | +67.1% | $196.8K | 2026-Q1 |
| OMERS ADMINISTRATION Corp | TRIM | 47,800 | 22,400 | -53.1% | $118.0K | 2026-Q1 |
| STATE STREET CORP | DOUBLED | 172,864 | 2,402,238 | +1289.7% | $15.8M | 2025-Q4 |
| BlackRock, Inc. | DOUBLED | 681,185 | 1,451,706 | +113.1% | $9.6M | 2025-Q4 |
| MARSHALL WACE, LLP | DOUBLED | 271,304 | 711,875 | +162.4% | $4.7M | 2025-Q4 |
| MORGAN STANLEY | ADD | 294,857 | 489,617 | +66.1% | $3.2M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 43,754 | 214,341 | +389.9% | $1.4M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 107,871 | 207,155 | +92.0% | $1.4M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 35,000 | 152,300 | +335.1% | $1.0M | 2025-Q4 |
| ExodusPoint Capital Management, LP | EXIT | 1,516,833 | 0 | -100.0% | $0.00 | 2025-Q4 |
| FMR LLC | DOUBLED | 221,000 | 8,787,052 | +3876.0% | $61.5M | 2025-Q3 |
| VANGUARD GROUP INC | DOUBLED | 1,056,922 | 2,415,244 | +128.5% | $16.9M | 2025-Q3 |
| ExodusPoint Capital Management, LP | NEW | — | 1,516,833 | — | $10.6M | 2025-Q3 |
| BlackRock, Inc. | ADD | 422,758 | 681,185 | +61.1% | $4.8M | 2025-Q3 |
| MORGAN STANLEY | ADD | 201,094 | 294,857 | +46.6% | $2.1M | 2025-Q3 |
| MARSHALL WACE, LLP | TRIM | 573,864 | 271,304 | -52.7% | $1.9M | 2025-Q3 |
| STATE STREET CORP | ADD | 97,335 | 172,864 | +77.6% | $1.2M | 2025-Q3 |
| UBS Group AG | DOUBLED | 5,073 | 126,402 | +2391.7% | $884.8K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 18,553 | 107,871 | +481.4% | $755.1K | 2025-Q3 |
12 unique insiders with 13 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | Feinberg Peter | Director | AWARD | 33,350 | — | — |
| Jun 11, 2026 | KEATING LAURIE | Director | AWARD | 33,350 | — | — |
| Jun 11, 2026 | CARPENTER ROBERT J | Director | AWARD | 33,350 | — | — |
| Jun 11, 2026 | HAUSMAN DIANA | Director | AWARD | 33,350 | — | — |
| Jun 11, 2026 | Schall Thomas J. | Director | AWARD | 33,350 | — | — |
| Mar 13, 2026 | Neufeld Leah R | CHIEF PEOPLE OFFICER | AWARD | 3,628 | $4.29 | $15.6K |
| Feb 3, 2026 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | AWARD | 344,000 | — | — |
| Feb 3, 2026 | Matushansky Igor | Chief Medical Officer | AWARD | 140,000 | — | — |
| Feb 3, 2026 | Zeskind Benjamin J. | PRESIDENT AND CEO | AWARD | 688,000 | — | — |
| Feb 3, 2026 | Brakewood Harold Eugene | Chief Business Officer | AWARD | 140,000 | — | — |
| Feb 3, 2026 | Morales Mallory | SVP Finance, CAO | AWARD | 140,000 | — | — |
| Feb 3, 2026 | Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY | AWARD | 176,000 | — | — |
| Feb 3, 2026 | Neufeld Leah R | CHIEF PEOPLE OFFICER | AWARD | 140,000 | — | — |
4 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 5.0/10.
NEUTRAL
INST-CLUSTER
3/10
Five mega-passive institutional investors (Vanguard, BlackRock, State Street, Fidelity, Morgan Stanl
Jun 11, 2026
BULLISH
8-K
7/10
Immuneering announced updated Phase 2a data for atebimetinib (IMM-1-104) in first-line pancreatic ca
Jun 1, 2026
BULLISH
PRESS-RELEASE
7/10
Immuneering reported Q1 2026 EPS of -$0.21, beating consensus of -$0.25 by 16%, with no revenue. The
May 15, 2026
NEUTRAL
DEFA14A
3/10
Analysis based on filing metadata only — document content was unavailable
Apr 20, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 4 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$17.00 mean target
+305.7% upside
Strong Buy (1.33)
$11.00 Low
$30.00 High
| Metric | Value |
|---|---|
| Current Price | $4.19 |
| Target Low | $11.00 |
| Target Mean | $17.00 |
| Target Median | $14.50 |
| Target High | $30.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.33) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.27 | $-0.31 | $-0.25 | 31.7% | +3.8% | 2↑ 2↓ | $0.0B | 0.0% | 6 |
| Next Q 2026-09-30 |
$-0.32 | $-0.37 | $-0.26 | 17.1% | +4.0% | 1↑ 2↓ | $0.0B | 0.0% | 6 |
| Current FY 2026-12-31 |
$-1.14 | $-1.30 | $-0.95 | 10.5% | +4.2% | 4↑ 1↓ | $0.0B | 0.0% | 6 |
| Next FY 2027-12-31 |
$-1.34 | $-1.71 | $-0.62 | -17.7% | +1.1% | 3↑ 1↓ | $0.0B | 0.0% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.273 | |
| 7d ago | $-0.273 | |
| 30d ago | $-0.284 | +0.011 |
| 60d ago | $-0.284 | +0.011 |
| 90d ago | $-0.355 | +0.082 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 19, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 9, 2026 | Needham | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
4 mentions
0 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 11, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 11, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 1, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 1, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
IMRX Phase 3 underway with first dose 11 June
▲ 1
💬 0
⚡ 0.5
IMRX is on sale now
▲ 1
💬 0
⚡ 0.3
Jun 11, 2026
fda
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
Jun 11, 2026
short_volume
Short Volume: IMRX — 55.4% short (0.5M / 0.9M)
Short: 491,181 | Exempt: 109 | TRF Vol: 886,788 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
other
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreati
Jun 1, 2026
short_volume
Short Volume: IMRX — 62.2% short (2.6M / 4.2M)
Short: 2,616,054 | Exempt: 222,417 | TRF Vol: 4,206,022 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: IMRX — 67.0% short (0.7M / 1.0M)
Short: 693,001 | Exempt: 6 | TRF Vol: 1,034,878 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)
May 26, 2026
short_volume
Short Volume: IMRX — 68.3% short (0.7M / 1.0M)
Short: 702,813 | Exempt: 52 | TRF Vol: 1,028,762 | Short Ratio: 68.3% | Off-exchange volume (dark pool + OTC)
May 21, 2026
fda
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherap
May 15, 2026
earnings
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
May 12, 2026
earnings_calendar
IMRX Q1 2026 Earnings Scheduled — 2026-05-12
Apr 21, 2026
fda
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
<p align="center"><em>- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an o
Apr 6, 2026
other
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
Apr 2, 2026
Clinical Trial
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Apr 2, 2026
clinical_trial_readout
T-60d Trial Readout: IMM-1-104 Monotherapy (Treatment Group A) (Phase 2)
Trial: A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Sponsor: Immuneering Corporation
Phase: Phase 2 | Stat
Apr 1, 2026
clinical_trial_readout
T-90d Trial Readout: IMM-1-104 Monotherapy (Treatment Group A) (Phase 2)
Trial: A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Sponsor: Immuneering Corporation
Phase: Phase 2 | Stat
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: IMM-1-104 Monotherapy (Treatment Group A) (Phase 2)
Trial: A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Sponsor: Immuneering Corporation
Phase: Phase 2 | Stat
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: IMM-1-104 Monotherapy (Treatment Group A) (Phase 2)
Trial: A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Sponsor: Immuneering Corporation
Phase: Phase 2 | Stat